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Abstract
Objective: Long-term evaluation of efficacy and quality of life after radical surgical approach for myasthenia gravis (MG). Comparison
between short-term follow-up and long-term outcome. Methods: All patients (n ¼ 26, 16 men and 10 women, mean age: 40.7 years)
underwent total transsternal thymectomy for MG between 1986 and 1989. Prospective analysis of the patients for short-term follow-up (mean
22.4 months) was published in 1991. The same group of patients was reevaluated in 2001 (range of follow-up 11.4–15.2 years) and assessed
according to the classification of Osserman and Oosterhuis. Results: Mean follow-up was 13.0 years (range 11.4–15.2 years). Two patients
were lost from follow-up and one died 4 years after thymectomy for reasons unrelated to MG (n ¼ 23). No early or late postoperative
mortality was observed. One sternal osteomyelitis occurred. Late postoperative morbidity included sternal instabilities (n ¼ 2), mild residual
thoracic pain (n ¼ 6), and hypertrophic scars (n ¼ 7). Five patients were rehospitalized for aggravating MG and needed plasmapheresis
(n ¼ 3) and intubation (n ¼ 1). Thirteen patients (56.5%) showed objective clinical improvement, including six patients (26.1%) with
complete remission. Eleven patients (47.8%) do not take any medication at all. Because some late relapse may occur several years after
operation, the rate of improvement decreased slightly, whereas the difference between short and long-term follow-up was not statistically
significant (P ¼ 0:405). Twenty patients (87%) returned to work, including part-time occupation (n ¼ 4). Fourteen patients (61%) are
performing sports regularly. Conclusions: Our data confirm that radical, transsternal thymectomy is an effective and safe therapeutic
modality for MG. Short-term results seem to deteriorate over time, therefore long-term studies for minimally invasive approaches have
to prove equal results before replacing the standard procedure. q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Myasthenia gravis (MG) is an acquired autoimmune
disease, with an incidence of about 0.3 and prevalence of
5.3 patients per 100 000 [1] with predominant onset in
females of the third decade without any ethnic, occupational
or endemic area predilection.
Most common symptoms are ptosis and diplopia in 65% of
all patients, but only 10% of them stay with the ocular form of
MG [2]. Mostly the disease gradually spreads to the skeletal
muscles with weakness of the proximal girdle and the bulbar
muscles with dysarthria, dysphagia and poor mastication.
Generalized weakness and involvement of respiratory
muscles are the final stage, which may lead to death without
treatment in more than 29% of these patients [1].
MG is a disorder of the neuromuscular transmission lead-
ing to fatigue and weakness after repetitive use of voluntary
muscles. The underlying autoimmune mechanism is the
production of specific antibodies directed against the acet-
ylcholine receptor (AChR) complex of the motor end-plate
with functional impairment and numeric decrease of these
receptors. The thymus, as the site of T-lymphocyte educa-
tion with resulting self-tolerance, is thought to be an integral
part in the pathogenesis of MG.
Thymectomy has been used to remove the main source of
antibody production since the first operation for MG by
Sauerbruch in 1911 [3]. After decades of transcervical
operation Blalock established the transsternal approach in
1936 and demonstrated the favourable effect of the opera-
tion on the course of MG, with only six cases published in
1941 [3]. In 1942 Keynes published 200 transsternal
thymectomies with a mortality of 33.5% for his first 20
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patients. Since 1965 Akamura and Crile promoted the trans-
cervical approach with certain advantages which were
confirmed by Papatestas and Cooper. Masaoka developed
the extended transsternal thymectomy in 1975 with good
success.
Selection of patients and choice of ideal operation tech-
nique remains controversial, especially since introduction of
minimally invasive approaches. Only few studies focus on
long-term outcome after thymectomy for MG. The aim of
the present study is to analyse long-term results with objec-
tive evaluation of efficacy and quality of life after a trans-
sternal radical approach for MG patients and most
importantly to compare short-term follow-up results with
long-term outcome.
2. Patients and methods
2.1. Inclusion criteria
Twenty-six consecutive patients underwent transsternal
radical thymectomy for MG at our institution between
1986 and 1989. Three patients (11.5%) presented with
thymoma. Diagnosis of MG was confirmed by clinical
assessment by a neurologist, and electromyographic studies,
edrophonium chloride (Tensilon) test and circulating acet-
ylcholine receptor (AChR) antibodies.
2.2. Indications for surgery
Indications for surgery included new onset of generalized
MG, failure of long-term conservative therapy (inclusively
ocular form of MG, which is usually associated with a posi-
tive clinical provocation tests) or myasthenic symptoms
with associated thymoma.
2.3. Operative technique
Median sternotomy is followed by opening the pleural
space. The mediastinum is thoroughly explored up to the
cervical thymic extension and laterally down to the phrenic
nerves. All thymic tissue and the entire pericardial and
mediastinal fat from the diaphragm to the thyroid is
removed en bloc.
2.4. Analysis of the group
Prospective analysis of short-term follow-up was
published in 1991 [4]. One patient of the original group
(n ¼ 27) had a malignant thymoma without symptoms and
was consequently excluded from further analysis. One
patient with thymoma was initially classified into the
wrong group. Except for these two changes the identical
group of patients was re-evaluated with the same criteria
by telephone interview and by written questionnaire in
March 2001. Two patients were lost from follow-up (back
in ex-Yugoslavia and in Libya, respectively) and one patient
died 4 years after thymectomy of lung embolism.
Two patients with thymoma remained in the analysis and
were not treated as a separate group.
One patient had already received a permanent tracheos-
toma 27 years before thymectomy and mediastinal irradia-
tion.
2.5. Data analysis
Data were collected on actual symptoms, changes in
health condition, hospitalizations, present medication and
physician’s care needed, local effect of surgery, effect of
pregnancies, hormone treatments and other medication as
well as capability to work and perform sports. Preoperative,
postoperative, and short-term follow-up data were taken
from the previous report.
For clinical assessment the actual severity of disease the
classification of Osserman (Table 1) and Oosterhuis (Table
2) were applied by the same neurologist as in the study
published 10 years ago.
2.6. Definitions
Patients without symptoms or medication for MG were
considered to have ‘complete remission’. ‘Improvement’
was defined as lower stage classification of Osserman or
Oosterhuis compared to the previous stage with or without
medical therapy, including patients with complete remis-
sion.
2.7. Statistical analysis
We applied the McNemar Chi-square test to compare
different stages of the same group over time. Univariate
analysis with Fisher’s test for evaluation of predictive
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Table 1
Osserman classification
I Indicating ocular myasthenia characterized by ptosis and
diplopia without involvement of other muscle groups
IIa Indicating slow onset, frequently ocular, gradually spreading
to the skeletal and bulbar musculature. Respiratory muscles are
spared
IIb Indicating gradual onset with dysarthria, dysphagia and poor
mastication more prevalent than in group IIa. Respiratory
muscles are spared
III Indicating rapid onset of severe bulbar and skeletal muscle
weakness with involvement of the respiratory muscles
IV Indicating severe myasthenia gravis developing at least 2 years
after onset of group I or II symptoms
Table 2
Oosterhuis classification
Class 0 Remission, no medication
Class 1 Minimal signs and symptoms
Class 2 Mildly disabled
Class 3 Moderately disabled
Class 4 Severely disabled
Class 5 Respiratory support needed
factors was used. A P-value of lass than 0.05 was considered
significant.
3. Results
3.1. Patients
The mean age of the 23 patients (14 men and nine
women) evaluated for long-term results was 38.1 years
(range 14.9–64.9) at the day of operation and 51.1 years
(range 26.6–77.6) at the time of re-evaluation. The mean
time of short-term follow-up was 22.4 months (range 6–53)
and 13.0 years (range 11.4–15.2) for the long-term outcome.
Mean duration of symptoms before operation was 6.2 years
(range 2 weeks to 29 years).
3.2. Early morbidity and mortality
In the group of 23 patients no mortality was observed. All
patients were extubated immediately after surgery; none
needed tracheotomy.
Postoperative mean hospital stay including the period at
the division of Neurology to stabilize MG was 9.4 days
(range 7–23). One patient (4%) developed sternal osteomye-
litis which needed intravenous antibiotic therapy and surgi-
cal debridement. We did not observe any other
postoperative complications such as pneumonia or phrenic
nerve palsy.
3.3. Late surgical complications
Two late reoperations were necessary: one for sternal
wire removal after 1 year, and one re-exploration because
of relapse of MG 9 years after the initial intervention for
thymoma. Remnant thymic tissue was resected without clin-
ical improvement (Osserman stage IIa).
Six patients (26%) had residual pain of the chest with
only one needing medication. Two patients had minor ster-
nal instability (9%) not requiring stabilization. Seven
patients (30%) were noted to have hypertrophic scars but
only one young woman was cosmetically disturbed. No
patient considered correction of the scar.
3.4. Short-term results
At short-term follow-up (mean of 22.4 months, range 6–
53) objective improvement in terms of Oosterhuis classifi-
cation was observed in 17 patients (73.9%), including seven
patients (30.4%) in complete remission. The accurate
assessment was as follows: seven patients in stage 0
(30.4%), seven in stage 1 (30.4%), five in stage 2
(21.7%), three in stage 3 (13.2%) and one patient in stage
4 (4.3%); no patient was in stage 5 (Fig. 1) [4].
The evaluation according to Oosterhuis shows that the
short-term follow-up was significantly better than preopera-
tion (mean value improved from 2.70 to 1.48), P ¼ 0:00016.
3.5. Late outcome
After 13.0 years of follow-up (range 11.4–15.2) six
patients (26%) were in complete remission and objective
improvements in terms of the Osserman classification was
achieved in 13 patients (56.5%), P ¼ 0:0013 (Fig. 2).
Five patients improved by one grade of Osserman classi-
fication (21.7%), seven by two grades (30.4%) and one by
three grades (4.3%). Nine patients (39.1%) did not change
the Osserman stage and one patient (4.3%) deteriorated by
one grade (Fig. 3).
Improvement was assigned to different groups as follows:
25% of the patients with Osserman stage I, 62.5% with stage
IIa and 62.5% stage IIb ,as well as 100% with stage IV
improved.
Slight deterioration of the 2 years’ result (mean value:
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Fig. 1. Staging of patients preoperatively, at 2, and at 13 years according to
Oosterhuis classification.
Fig. 2. Staging of patients preoperatively and at 13 years according to
Osserman classification.
1.48) was observed 13 years after thymectomy (mean value:
1.56), but the difference did not reach significance, P ¼
0:405 (Fig. 1). This tendency was due to worsening of
MG in eight patients (35%).
Twenty-two hospital admissions including five injuries
were necessary for 15 patients in the course of a mean 13
years: five times due to aggravation of MG of which two
with myasthenic crisis, three needing plasmapheresis and
one intubation. No cholinergic crisis nor brittle myasthenia
was observed. Two patients (8.7%) developed a malignant
disease: lymphoma and cancer of the uterus, respectively.
At the time of assessment 11 patients (47.8%) do not take
any myasthenic medication and two (9%) need reduced
therapy. Eleven patients (48%) still require prostigmine
and six (26%) immunosuppressive therapy alone or in
combination (Fig. 4).
3.6. Predictive factors
Classic predictive factors such as gender, age, severity of
MG, AChR antibody and duration of symptoms were tested
for complete remission and clinical improvement. In our
study only female gender (nine of 23 patients) is a predictive
factor for postoperative improvement (89% success versus
36% in males), P ¼ 0:029.
In the univariate analysis factors such as age , 40 years
(n ¼ 12), duration of preoperative symptoms , 1 year
(n ¼ 10) and severe stage Osserman . IIb (n ¼ 11) did
not significantly influence the outcome.
For complete remission no predictive factor could be
detected. In contrast to other studies less severe initial
disease (Osserman stage I–IIa) resulted in better remission
rates (42 vs. 9%).
All patients had an AChR antibody serology preopera-
tively done, of which only four (17%) were negative
(three with Osserman stage I and one with stage IV). Preo-
perative presence of AChR antibody did not predict better
outcome (50 vs. 58%).
3.7. Subjective evaluation and patients’ quality of life
Subjectively, 19 patients (82.6%) consider themselves to
be in either very good condition (n ¼ 6), good condition
(n ¼ 4) or better than before surgery (n ¼ 9). Three patients
did not observe any change (13.1%) and one feels worse
than before surgery (4.3%).
Fifteen patients (65.2%) are working full-time, of which
four women are housekeeping. One patient (4.3%) worked
full-time until his retirement. Three patients (13.1%) experi-
enced progressive incapability to work and are actually
retired. One patient (4.3%) is working at a reduced level
because of MG and three (13.1%) are not able to work.
Fourteen patients (61%) perform some kind of sport regu-
larly.
Of six children born by three women, none showed any
neonatal form of transmitted MG. Only one caesarean
section was needed. Five women used oral contraceptives
and never experienced any change of myasthenic symp-
toms.
No patient ever sensed any worsening of MG after taking
different medication.
3.8. Histology
Histological examination of the thymus showed atrophy
(n ¼ 7), normal thymus (n ¼ 6), lymphoid follicles (n ¼ 6),
germinal centres (n ¼ 7), hyperplasia (n ¼ 2), and two
thymoma stage I of Masaoka. Five times (22%) aberrant
ectopic thymic tissue was found: four times in pericardial
fat and once in the aorto-pulmonary window.
4. Discussion
This paper reports the longest mean follow-up after
thymectomy for MG (Table 3). There is a growing interest
in these long-term results as new operative techniques such
as minimally invasive approaches have been developed.
These techniques have to prove equal long-term outcome
compared to the gold standard which still is the radical
transsternal thymectomy. With this study we confirm the
results of previous series which demonstrated a rate of
complete remissions of about 30%. We cannot demonstrate
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Fig. 3. Grade of improvement at 13 years according to Osserman classifica-
tion.
Fig. 4. Actual medication: P, prostigmine; A, azathioprine; p, prednisone;
C, cyclosporine.
a statistically significant difference between the results after
2 and 13 years. More late deteriorations (35%) than late
improvements (22%) have been observed which stands in
contrast to previously published series.
It is known that analysis of outcome of chronic and rare
diseases with unpredictable and fluctuating courses is diffi-
cult. In addition a number of different classifications for MG
are used throughout the literature: Osserman, Osserman
modified, Oosterhuis, Myasthenia Gravis Foundation of
America, Besinger score and de Filippini, which all try to
integrate the Neurologist’s assessment and the patient’s
perception of disease-related symptoms and limitations.
Definitions as for ‘complete remission’ or ‘improvement
rate’ are inconsistent in the literature. Furthermore, the
groups in published studies are very heterogeneous. They
contain mixed pathologies (invasive thymoma), do not
differentiate between operative techniques, and vary in
patient selection and indications for thymectomy. Even
this presented group is small in comparison with previous
publications; the observation period is very long, the group
of patients is homogeneous, and only two patients were lost
from follow-up.
To our knowledge no randomized study has ever been
performed, neither between medical and surgical approach
nor between different surgical procedures. The beneficial
effect of thymectomy for MG is generally accepted and
can be confirmed with the present study. The remission
and improvement rate after surgery cannot be reached
with conservative therapy, despite the fact that spontaneous
remission may occur in 11–14% [5]. It is often forgotten that
the mortality rate of non-operated patients with MG was as
high as 26% and has decreased dramatically after the intro-
duction of early thymectomy [6]. Our series also confirms
the safety of this operative procedure, with no postoperative
mortality and a minimal number of early and late complica-
tions, and therefore underlines the importance of thymect-
omy as a cornerstone of the treatment of MG.
We can demonstrate that 57% of the patients have a
significant objective improvement including 26% of the
patients with complete remission (no symptoms nor medi-
cation for MG) after 13 years of follow-up.
Other much larger studies demonstrated this fact, but no
study so far has such a long mean follow-up. The loss of 8%
(2/26) of the patients after 13 years is very acceptable. In
contrast to other series with long-term evaluation [7,8] we
did not observe as many postoperative late remissions as
expected from the literature, but a number of late relapses
resulting in an overall slight decrease of improvement rate
over the entire observation period. This finding indicates
that every new technique has to be evaluated carefully and
honestly for long-term results despite the advantages of the
minimal invasive approach by either thoracoscopy [9–12] or
transcervical procedure [13–15] with better acceptance by
patients and neurologists.
We still favour the transsternal radical approach at our
centre, as we have detected extrathymic fat tissue in 22% of
the patients. In the literature this rate is even as high as
39.5% [16]. It is known that only 4.5 g of remnant thymic
tissue may lead to symptoms [17] and therefore radical
thymectomy has been chosen to obtain maximal therapeutic
benefit [18]. The transverse sternotomy advocated by some
authors does not seem to ameliorate the results of the stan-
dard procedure [19]. The extended thymectomy does not
result in a better remission rate (38%), perhaps because of
ectopic thymic tissue (like thyroid or tonsil) [20].
Almost half of the patients in the present study (48%)
currently do not need any myasthenic medication and in
9% the medication could be strongly reduced postopera-
tively. We did not observe clinically relevant complications
due to immunosuppressive therapy, particularly conditions
after long-term steroid therapy such as diabetes, hyperten-
sion, gastric ulcer, osteoporosis or infection.
Additionally it has been reported that, due to a reduced
immunosuppressive regimen, the risk of developing malig-
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Table 3
Literature overviewa
First author [Ref.] Year Approach n Remission (%) Improvement (%) Follow-up (years)
Mack [11] 1996 VATS 33 18 70 1.9
Yim [9] 1995 VATS 113 11 72 2.1
Mineo [10] 2000 VATS 31 36 60 3.3
Jaretzki [20] 1988 EXT 95 38 56 3.3
Hatton [21] 1989 TS 52 27 35 3.8
Klein [22] 1999 TS 51 40 47 3.9
Budde [19] 2001 TSt 113 21 54 4.3
Calhoun [14] 1999 TC 100 35 50 5.0
Bush [8] 1996 TS 86 19 52 7.7
Masaoka [7] 1996 TS 375 47 42 7.9
Bril [13] 1998 TC 52 44 46 8.0
Papatestas [6] 1987 TC/TS 962 32 – 10.0
Roth (this study) 2001 TS 26 26 31 13.0
a TS, transsternal thymectomy; TC, transcervical thymectomy; EXT, extended thymectomy; TSt, transsternal transverse thymectomy; VATS, video-assisted
thoracic thymectomy.
nant diseases can be reduced by 50% after thymectomy
from 8 to 4% after 10 years’ observation [6]. In our series
we observed two malignancies in 13 years. Surprisingly we
did not observe associated immunological diseases such as,
for example, Hashimoto thyroiditis which is reported to
occur in 10% of patients with MG.
Indeed, 70% of the patients did not consult a specialist
such as a neurologist or ophthalmologist for their disease,
and 39% of all patients did not consult any physician at the
time of the assessment.
In summary, the quality of life of the group of patients in
this study is very good with nearly 90% of the patients back
to work after surgery (including partial work) and two-thirds
(65.2%) actually working full-time (including 17% at
home). Regular sports such as walking, hiking, horse riding,
cycling, swimming, skiing or shooting are performed by
61%. To improve cosmetic results we use a transverse
curved skin incision for young women which will be
completely covered under a bra. The relatively long post-
operative stay at hospital in the 1980s cannot be compared
with patient management nowadays.
Only female gender has been identified as a predictive
factor in our study. Other often mentioned prognostic
factors [19] such as age ð,40 years), duration of preopera-
tive symptoms ð,1 year) and severity (stage
Osserman . IIbÞ did not influence the outcome in a statis-
tically significant way. This might be because of the small
number of patients, as for example 75% of the patients
under 40 years improved in contrast to 36% over 40 years
(P ¼ 0:10).
Compared to previously published series [6–8,10–14,19–
22], our results after 13 years of follow-up show similar
results for complete remission with a rate of 26% (11–
47%). The improvement rate of 31% was lower than in
published studies, ranging from 34 to 70% (Table 3).
These results may be influenced by an unfavourable
inverted gender distribution (male/female ratio 7:4) in
combination with long preoperative duration of symptoms
up to 29 years, as it is known that MG becomes fixed after
more than 15 years in the course of disease (burn-out stage)
[23].
Analyzing the improvement rates of different studies
(Table 3) in correlation to observation time we note that
improvement was becoming worse with duration of obser-
vation, although most individual studies paradoxically indi-
cate improvement of outcome over time. In this respect a
careful meta-analysis of these studies is needed.
We also noted that the complete remission rate of patients
operated on by a video-assisted thoracoscopic approach was
low [10–12]. If the improvement rate is indeed declining
over time, long-term studies after minimally invasive
thymectomy might show surprising results.
In conclusion, the transsternal radical thymectomy
remains the gold standard for thymectomy in MG patients.
Two-thirds of the patients with a mean follow-up of 13 years
lead a normal life with normal everyday activity including
regular sports. Short-term results seem to predict long-term
outcome, but careful review of the literature seems to indi-
cate a deterioration of the initial results over time. There-
fore, long-term studies for minimally invasive thymectomy
are warranted to establish equal long-term results.
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